NEUMÜNSTER, Germany, July 29, 2024 – PRESS RELEASE – Tilray Brands Inc., a global leader in medical cannabis research, cultivation, production and distribution, announced that Aphria RX GmbH (Aphria RX) has received a trading license, which will allow it to sell and distribute a broad range of medical cannabis products to pharmacies, hospitals and medical wholesalers throughout Germany.
“This milestone of Aphria RX obtaining both its new cultivation license as well as its trading license further expands Tilray’s leadership in medical cannabis research, cultivation, production and distribution in Germany and once again proves our commitment to be one of the most responsible, trusted and market leading cannabis companies in the world with a portfolio of innovative and high-quality products that address the needs of patients,” said Denise Faltischek, chief strategy officer and head of International at Tilray. “We remain dedicated to advocating for responsible cannabis regulations, education and research and accessibility to high-quality medical cannabis.”
With both cannabis cultivation and trade licenses, Tilray is now in a strong position to fully leverage the growing market opportunity in Germany, further expanding Tilray’s position as a global leader in cannabis research, cultivation, production and distribution.
As a leading and trusted medical cannabis company, Tilray strongly believes that these developments will have a positive impact on the health and wellbeing of patients in Germany. Tilray is committed to working with the German government and all stakeholders to promote improved access to medical cannabis, optimize care for patients, and advance the science of cannabis.
